<DOC>
	<DOCNO>NCT01687179</DOCNO>
	<brief_summary>Specific Aim 1 : To investigate whether , Lymphangioleiomyomatosis ( LAM ) patient , combination sirolimus hydroxychloroquine safe well tolerate Specific Aim 2 : To investigate whether , LAM patient , 6 month combination therapy sirolimus hydroxychloroquine result improvement indicator disease , whether gain sustain stop therapy . Specific Aim 3 : To investigate potential role LAM-specific peripheral blood signature predict rate disease progression determine responsiveness combination therapy . This phase I dose escalation study combination sirolimus ( 2 mg adjust keep trough level 5-15 ng/ml ) hydroxychloroquine ( 200 mg 400 mg ) take orally daily . Up 18 adult woman LAM enrol .</brief_summary>
	<brief_title>Safety Study Sirolimus Hydroxychloroquine Women With Lymphangioleiomyomatosis</brief_title>
	<detailed_description>This phase I dose escalation study combination sirolimus ( 2 mg adjust keep trough level 5-15 ng/ml ) hydroxychloroquine ( 200 mg 400 mg ) take orally daily 6 month . The study conduct 2 site . Up 18 adult woman LAM enrol , recruit site recruit 8-12 subject . The protocol use follow eligibility criterion .</detailed_description>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Female age 18 old Ability give inform consent Diagnosis LAM define typical cystic change CT plus : biopsy cytology tissue demonstrate LAM angiomyolipoma , chylothorax , lymphangioleiomyoma , tuberous sclerosis serum VEGFD great equal 800pg/ml Postbronchodilator FEV1 equal less 80 % predict DLCO equal equal less 70 % predict , RV &gt; 120 % predict baseline Women childbearing potential must agree use 2 form barrier contraception 8 week last dose medication . History intolerance mTOR inhibitor History intolerance hydroxychloroquine History severe psoriasis History porphyria cutanea tarda Uncontrolled intercurrent illness Pregnant , breast feeding , plan become pregnant next year Inadequate contraception Significant hematological hepatic abnormality Use investigational drug within 30 day study start Inability attend schedule clinic visit Inability perform PFTs Creatinine &gt; 2.5mg/dL Recent pneumothorax within 8 week screen History malignancy last 2 year basal cell skin cancer Use estrogen contain medication within 30 day screen Abnormal G6PD level baseline Preexisting maculopathy retinopathy Preexisting myopathy Currently take doxycycline , metformin , lupron , simvastatin Unable undergo CT MRI History seizure within last year Hepatitis B , C , HIV positive serology Use alternative medical therapy LAM least 6 week prior study participation History myocardial infarct , angina , stroke related atherosclerosis History cardiomyopathy Previous lung transplant Surgery ( involve entry body cavity require 3 stitch ) within 2 month initiation study drug Uncontrolled cholesterol &gt; 350mg/dL , triglyceride &gt; 400mg/dL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LAM</keyword>
	<keyword>TSC</keyword>
	<keyword>lymphangioleiomyomatosis</keyword>
</DOC>